**Amgen director Amy E. Miles reported an equity-award transaction involving Amgen common stock on May 19, 2026.** The filing indicates that Miles received Restricted Stock Units, or RSUs, under the **Amgen Inc. 2009 Director Incentive Program**, as amended, which operates under the company’s **Second Amended and Restated 2009 Equity Incentive Plan**. The RSUs **vested immediately**. Under the plan terms described in the filing, vested RSUs are payable in shares of **Amgen Inc. common stock** on a **one-for-one basis**. Directors may also elect to defer receipt of the shares, in which case the stock is delivered according to the director’s chosen deferral schedule rather than immediately upon vesting. The filing does not show in the provided text the number of RSUs granted, the transaction code, the deemed grant price, or Miles’s total beneficial ownership after the transaction. However, the notes make clear that the reported change relates to a director equity compensation award rather than an open-market purchase or sale. The filing also states that Miles’s reported shares include **408 dividend equivalents**, or DEs, granted under Amgen’s equity incentive plan and subject to a qualifying dividend reinvestment plan. These dividend equivalents are credited to unvested RSUs and are paid out in Amgen common shares on a **one-for-one basis** according to the applicable vesting schedule, with cash paid for any remaining fractional share amount. Miles signed the report on **May 21, 2026**. The key takeaway is that Amgen reported a routine director compensation-related equity event for Miles, involving immediately vested RSUs and related dividend equivalents tied to Amgen common stock.